B-hTNFRSF4 (OX40) Mice

Basic Information

Strain Name
C57BL/6-Tnfrsf4tm1( TNFRSF4)Bcgen/Bcgen
Stock Number
110014
Common Name
B-hTNFRSF4(OX40) Mice
Source/Investigator
Bcgen (Beijing Biocytogen Co., Ltd)
Related Genes
Tnfrsf4 (tumor necrosis factor receptor superfamily, member 4)
Species
C57BL/6
Appearance
Black
Genotypes
Homozygous

Description

OX40, also known as Tnfrsf4 (Tumor necrosis factor receptor super family, member 4), is mainly expressed on the surface of activated CD4 + and CD8 + T cells, and its binding with the OX40 ligand can stimulate CD8 + T cell activation. The coactivation of OX40/OX40L enhances T cell function, including cytokine production, proliferation and T cell survival. An OX40 agonist can reduce Regulatory T cells (Tregs) and improve anti-tumor activity.

Targeting Strategy

Details

Phenotype

mRNA Expression Analysis

B-hTNFRSF4OX40-Mice-details-mrna-expression-analysis

 

 

 

 

 

RT-PCR analysis of OX40 mRNA expression. The hOX40, but not mOX40, mRNA was detectable in splenocytes of the homozygous B-hOX40 mice.

 

Protein Expression Analysis

 

Splenocytes from both wild type (WT)C57BL/6 and homozygous B-hOX40 mice were analyzed by flow cytometry. Mouse OX40 + T cells were detectable in the WT mice, while human OX40 + T cells were detectable in the homozygous B-hOX40 mice.

 

Application

 

OX40 Efficacy Evaluation (different doses)

B-hTNFRSF4OX40-Mice-details-ox40-efficacy-evaluation-diff-doses

 

 

 

 

 

 

Murine colon cancer cells (MC38) were subcutaneously implanted into heterozygous B-hOX40 mouse. Mice were divided into control and experimental groups (n=5) when the tumor size was about 100 mm3. Anti-hOX40 antibody significantly inhibited tumor growth in the heterozygous B-hOX40 mice at 3 different doses, suggesting that B-hOX40 mouse model is an effective tool for in vivo hOX40 antibody efficacy study. (A) Tumor average volume ± SEM, (B) Mice average weight ± SEM.

 

OX40 Efficacy Evaluation

B-hTNFRSF4OX40-Mice-details-ox40-efficacy-evaluation

 

 

 

 

 

 

Murine colon cancer cells (MC38) were subcutaneously implanted into homozygous B-hOX40 mouse. Mice were divided into control and experimental groups (n=5) when the tumor size was about 100 mm3. Anti-hOX40 antibody significantly inhibited tumor growth in the homozygous B-hOX40 mice, suggesting that B-hOX40 mouse model is an effective tool for in vivo hOX40 antibody efficacy study. (A) Tumor average volume ± SEM, (B) Mice average weight ± SEM.

 

Human OX40 Antibody (MOXR0916 Analog) Efficacy Evaluation

 

 

 

 

 

 

Murine Colon cancer cells were subcutaneously implanted into the homozygous B-hOX40 mice. The mice were divided into control and treatment groups as the tumor volume was 150±50mm3 (n=5). The result indicated that B-hOX40 mouse
model was an effective tool for in vivo hOX40 antibody efficacy study. (A) Tumor average volume ± SEM, (B) Mice average weight ± SEM.

 

Human OX40 antibody(MOXR0916 Analog)efficacy evaluation

B-hTNFRSF4OX40-Mice-details-human-ox40-antibody

 

 

 

 

 

 

Murine Colon cancer cells were subcutaneously implanted into the homozygous B-hOX40 mice. The mice were divided into control and treatment groups as the tumor volume was 150±50mm3 (n=5). The result indicated that B-hOX40 mouse
model was an effective tool for in vivo hOX40 antibody efficacy study. (A) Tumor average volume ± SEM, (B) Mice average weight ± SEM.

References

1. J Immunol. 2013 Oct 1;191(7):3641-50. doi:10.4049/jimmunol.1202752. Epub 2013 Sep 6.
2. Cancer Res. 2013 Dec 15;73(24):7189-7198.doi: 10.1158/0008-5472.CAN-12-4174. Epub 2013 Oct 31.
3. Clin Cancer Res. 2013 Mar 1;19(5):1044-53.doi: 10.1158/1078-0432.CCR-12-2065.
4. Annu Rev Immunol. 2010;28:57-78. doi: 10.1146/annurev-immunol-030409-101243.

Back to top